Serum Carcinoembryonic Antigen Levels before Initial Treatment are Associated with EGFR Mutations and EML4-ALK Fusion Gene in Lung Adenocarcinoma Patients |
Wang, Wen-Tao
(Department of Thoracic Surgery, the Affiliated Tumor Hospital of Zhengzhou University)
Li, Yin (Department of Thoracic Surgery, the Affiliated Tumor Hospital of Zhengzhou University) Ma, Jie (Department of Molecular Pathology, the Affiliated Tumor Hospital of Zhengzhou University) Chen, Xiao-Bing (Department of Oncology, the Affiliated Tumor Hospital of Zhengzhou University) Qin, Jian-Jun (Department of Thoracic Surgery, the Affiliated Tumor Hospital of Zhengzhou University) |
1 | Shoji F, Yoshino I, Yano T, et al (2007). Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer, 110, 2793-8. DOI ScienceOn |
2 | Screaton RA, Penn LZ and Stanners CP (1997). Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation. J Cell Biol, 137, 939-52. DOI ScienceOn |
3 | Shaw AT, Kim DW, Nakagawa K, et al (2013). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med, 368, 2385-94. DOI ScienceOn |
4 | Shaw AT, Yeap BY, Mino-Kenudson M, et al (2009). Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol, 27, 4247-53. DOI ScienceOn |
5 | Soda M, Choi YL, Enomoto M, et al (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448, 561-6. DOI ScienceOn |
6 | Usuda K, Sagawa M, Motono N, et al (2014). Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive? Asian Pac J Cancer Prev, 15, 657-62. 과학기술학회마을 DOI ScienceOn |
7 | Yatabe Y and Mitsudomi T (2007). Epidermal growth factor receptor mutations in lung cancers. Pathol Int, 57, 233-44. DOI ScienceOn |
8 | Zhang Y, Wang Q, Han ZG, et al (2013). Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups. Asian Pac J Cancer Prev, 14, 2879-83. 과학기술학회마을 DOI ScienceOn |
9 | Ordonez C, Screaton RA, Ilantzis C, et al (2000). Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res, 60, 3419-24. |
10 | Miyanaga A, Shimizu K, Noro R, et al (2013). Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. BMC Cancer, 13, 262. DOI ScienceOn |
11 | Nagai Y, Miyazawa H, Huqun, et al (2005). Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res, 65, 7276-82. DOI ScienceOn |
12 | Okamoto T, Nakamura T, Ikeda J, et al (2005). Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. Eur J Cancer, 41, 1286-90. DOI ScienceOn |
13 | Ravindranath N, Wion D, Brachet P, et al (2001). Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl, 22, 432-43. |
14 | Ozgul MA, G KRL, Seyhan EC, et al (2013). The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer. Multidiscip Respir Med, 8, 69. DOI ScienceOn |
15 | Planchard D (2013). Identification of driver mutations in lung cancer: first step in personalized cancer. Target Oncol, 8, 3-14. DOI ScienceOn |
16 | Qin HF, Qu LL, Liu H, et al (2013). Serum CEA level change and its significance before and after gefitinib therapy on patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4205-8. 과학기술학회마을 DOI ScienceOn |
17 | Scaltriti M and Baselga J (2006). The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res, 12, 5268-72. DOI ScienceOn |
18 | Herbst RS (2004). Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys, 59, 21-6. DOI ScienceOn |
19 | Dearden S, Stevens J, Wu YL, et al (2013). Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol, 24, 2371-6. DOI ScienceOn |
20 | Fukuoka M, Wu YL, Thongprasert S, et al (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 29, 2866-74. DOI ScienceOn |
21 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
22 | Gahr S, Stoehr R, Geissinger E, et al (2013). EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer, 109, 1821-8. DOI ScienceOn |
23 | Horinouchi H, Sekine I, Sumi M, et al (2012). Brain metastases after definitive concurrent chemoradiotherapy in patients with stage III lung adenocarcinoma: carcinoembryonic antigen as a potential predictive factor. Cancer Sci, 103, 756-9. DOI ScienceOn |
24 | Ishiguro F, Fukui T, Mori S, et al (2010). Serum carcinoembryonic antigen level as a surrogate marker for the evaluation of tumor response to chemotherapy in nonsmall cell lung cancer. Ann Thorac Cardiovasc Surg, 16, 242-7. |
25 | Maemondo M, Inoue A, Kobayashi K, et al (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362, 2380-8. DOI ScienceOn |
26 | Blumenthal RD, Hansen HJ and Goldenberg DM (2005). Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Res, 65, 8809-17. DOI ScienceOn |
27 | Aydiner A, Yildiz I and Seyidova A (2013). Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status. Asian Pac J Cancer Prev, 14, 3255-61. 과학기술학회마을 DOI ScienceOn |
28 | Benchimol S, Fuks A, Jothy S, et al (1989). Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell, 57, 327-34. DOI ScienceOn |
29 | Cook MB, Dawsey SM, Freedman ND, et al (2009). Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev, 18, 1174-82. DOI ScienceOn |
30 | Bergman B, Brezicka FT, Engstrom CP, et al (1993). Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer. Eur J Cancer, 29A, 198-202. |
31 | Wu YC, Chang IC, Wang CL, et al (2013). Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One, 8, e70839. DOI |
32 | Li Y, Li Y, Yang T, et al (2013). Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One, 8, e52093. DOI |
33 | Choi YL, Sun JM, Cho J, et al (2013). EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS One, 8, e56011. DOI |
![]() |